Back to discover
Disease
Salmonella Infections
Late-stage therapeutic developmentEmerging researchRising momentum
4
Publications
6
Clinical trials
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Microbiome diversity protects against pathogens by nutrient blocking.
Research2023-12-15Science (New York, N.Y.)
Research2019-11-14Proceedings of the National Academy of Sciences of the United States of America
<i>Salmonella</i> Pathogenicity Island 1 (SPI-1) and Its Complex Regulatory Network.
Research2019-07-31Frontiers in cellular and infection microbiology
Research2014-02-11BMC public health
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
- Q3 2026A Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in Africa
- Q2 2028A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa
Major developments
Upcoming trial readoutImportant
Results expected Q3 20262026-05-19
Upcoming trial readoutImportant
Results expected Q2 20282026-04-20
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-05-19A Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in AfricaResults expected Q3 2026
- 2026-04-20A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in AfricaResults expected Q2 2028
Recently completed
- 2026-02-28The Development of a Non-typhoidal Salmonella Human Challenge Model: A Safety and Dose Escalation StudyPrimary completion
Activity timeline4
- 2026-05-19ClinicalA Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in AfricaResults expected Q3 2026
- 2026-04-20ClinicalA Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in AfricaResults expected Q2 2028
- 2026-02-28ClinicalThe Development of a Non-typhoidal Salmonella Human Challenge Model: A Safety and Dose Escalation StudyPrimary completion
- 2025-11-28ClinicalA Phase 1/2a, Observer-blind, Randomized, Controlled, Two-stage, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Response of the Trivalent Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) and Typhoid Fever in Healthy European and African AdultsResults posted
Clinical trials
The current development programme across all trial phases.
Clinical programme
6
3
1
3
Late-stage studies
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20142023
Most influential
Recent publications
Major themes8
- Gastrointestinal Microbiome1
- Gene Regulatory Networks1
- Genomic Islands1
- Host-Pathogen Interactions1
- Klebsiella Infections1
- Klebsiella pneumoniae1
- Salmonella Infections1
- Salmonella typhimurium1
Leading journals4
- BMC public health1
- Frontiers in cellular and infection microbiology1
- Proceedings of the National Academy of Sciences of the United States of America1
- Science (New York, N.Y.)1
Leading researchers8
- B N Araujo E1
- Bakkeren E1
- Beraza N1
- Bowles KM1
- Brooke RJ1
- Cassini A1
- Cunrath O1
- Di Palma F1
Affiliations (unnormalised)6
- Centre for Immunity1
- Earlham Institute1
- First Hospital of Jilin University1
- Gut Microbes and Health Institute Strategic Programme1
- Kennedy Institute of Rheumatology1
- Norfolk and Norwich University Hospitals NHS Trust1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Infections with bacteria of the genus SALMONELLA.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.